Neuroscience Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neuroscience

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Oravetz who wrote (233)	6/12/2002 12:55:28 PM
From: Jim Oravetz	Read Replies (1) of 278

Nymox Alzheimer's Treatment -2: Plans Human Trials DOW JONES NEWSWIRES MAYWOOD, N.J. -- Nymox Pharmaceutical Corp. (NYMX) reported progress with a new Alzheimer drug candidates in pre-clinical laboratory studies. In a press release Wednesday, the company said its NXD-9062 was found to work in animals by inhibiting cell damage similar to that found in Alzheimer's disease brain, in tests in laboratory and animal models. The drug was safely tolerated. Nymox said it plans to complete the steps to target NXD-9062 for regulatory review this year and begin human trials. The company said it believes the drug has "enormous potential" because "there is still no truly effective therapy that stops or significantly retards the disease." Nymox currently markets AlzheimAlert, a non-invasive urine test that helps diagnose Alzheimer's disease, providing physicians aid by detecting the presence of neural thread protein, which is elevated in the urine of patients with Alzheimer's disease. Company Web site: nymox.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next